The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Weak to moderate cytoplasmic staining, combined with cases of nuclear positivity was observed in most malignancies. Malignant gliomas and several malignant melanomas were negative.
A majority of malignant cells displayed moderate to strong nuclear and cytoplasmic positivity. Prostate and liver carcinomas were mainly negative.
Malignant tissues exhibited nuclear and cytoplasmic staining of varying intensity. Cases of malignant lymphomas, ovarian, thyroid, lung and liver cancers displayed strong nuclear and/or cytoplasmic immunoreactivity. Testicular cancers were in general negative. Most other cancers were mainly weakly to moderately stained.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
